Samy Louafi, Valérie Boige, Michel Ducreux, Luminita Bonyhay, Touraj Mansourbakht, Thierry de Baere, Amani Asnacios, Laurent Hannoun, Thierry Poynard and Julien Taïeb Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepatocellular carcinoma (HCC) Cancer 109
Article first published online: 1 MAR 2007 | DOI: 10.1002/cncr.22532
Thirty-four patients with advanced HCC previously untreated were prospectively enrolled in this phase II trial to evaluated a bimonthly GEMOX regimen (gemcitabine 1000mg/m2 D1; oxaliplatin 100mg/m2 D2). Thirty-two patients were assessable for efficacy and 33 for toxicity. No toxic deaths occurred. Hematological grade 3-4 toxicity consisted of thrombocytopenia (27%), neutropenia (24%); grade 3.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field